目的 觀察阿加曲班注射液治療發(fā)病48 h內(nèi)基底動脈尖綜合征的臨床療效及安全性。方法 收集2017年1月—2022年5月在銅陵市人民醫(yī)院治療的56例基底動脈尖綜合征患者，隨機(jī)分為對照組和治療組，每組各28例。對照組予以包括抗血小板聚集、改善腦循環(huán)、他汀、調(diào)控血糖、血壓等常規(guī)治療。治療組在常規(guī)治療的基礎(chǔ)上靜脈滴注阿加曲班注射液，前2 d 60 mg/d持續(xù)靜脈泵入，持續(xù)48 h，后改為10 mg/次，2次/d，持續(xù)5 d。觀察兩組患者臨床療效，比較治療前后兩組患者美國國立衛(wèi)生研究院卒中量表（NIHSS）評分和Barthel指數(shù)（BI）評分。結(jié)果 治療后，對照組和治療組的總有效率分別為64.29%和89.28%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組NIHSS評分均低于治療前（P＜0.05），BI評分治療組顯著高于治療前（P＜0.05），且治療組NIHSS評分和BI評分顯著好于對照組（P＜0.05）。結(jié)論 阿加曲班治療發(fā)病后48 h內(nèi)基底動脈尖綜合征患者的臨床療效和預(yù)后良好，且不增加藥物不良反應(yīng)的發(fā)生率。

Objective To observe the clinical efficacy and safety of agatroban in treatment of patients with top of basilar artery syndrome within 48 hours after onset. Methods Patients (56 cases) with basilar apex syndrome in Tongling People' Hospital from January 2017 to May 2022 were randomly divided into control and treatment group, and each group had 28 cases. Patients in the control group was administered with routine treatment, including anti-platelet aggregation, improvement of cerebral circulation, statin, regulation of blood glucose, blood pressure and so on. Patients in the treatment group were iv administered with Argatroban Injection on the basis of routine treatment, 60 mg/d was continuously pumped intravenously for 48 h in the first 2 days, and then changed to 10 mg/time, twice daily, and they were treated for 5 d. After treatment, the clinical evaluation was evaluated, and the NIHSS scores and Barthel index in two groups before and after treatment were compared. Results After treatment, the total effective rates of the control group and the treatment group were 64.29% and 89.28%, respectively, with a statistically significant difference between the two groups (P < 0.05). After treatment, NIHSS scores in two groups were significantly lower than those before treatment (P < 0.05), while BI scores in treatment group were significantly higher than those before treatment (P < 0.05), and the scores of NIHSS and BI in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Argatroban has good clinical efficacy and prognosis in patients with basilar artery tip syndrome within 48 h after onset, and does not increase the incidence of adverse drug reactions.

R971